Thetis Receives $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease

Resolvin-based agent targets inflammation resolution and tissue regeneration without immunosuppression BRANFORD, CT – (GlobeNewswire – November 16, 2017) – Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). The […]

Thetis Announces Pre-Clinical Data on TP-252

Preclinical data shows equivalence of TP-252 and EPA-FFA in modulating inflammatory eicosanoid profiles within the colon EPA-FFA has demonstrated clinical efficacy in reducing the rate of relapse in ulcerative colitis BRANFORD, CT May 8, 2017 – Thetis Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs for inflammatory bowel disease (IBD), today announced pre-clinical data […]

Thetis Announces Immuno-Resolving Therapies for Inflammatory Bowel Disease

– Lead candidate TP-252 expected to begin clinical studies in 2018 BRANFORD, CT– (May 5, 2017) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing small molecule drugs for treatment of gastrointestinal diseases, announced two development candidates, TP-252 and TP-317, for treatment of inflammatory bowel disease (IBD). Gary Mathias, co-founder and chief executive officer, commented, […]

Thetis Awarded Key Patent on HEALER Technology

SOUTHPORT, CT–(Marketwired – Jan 27, 2016) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for our lead development candidates, TP-252 for familial adenomatous polyposis. The allowed claims include pharmaceutical compositions that are mineral amino-acid […]